Literature DB >> 19362088

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Jorge A Marrero1, Ziding Feng, Yinghui Wang, Mindie H Nguyen, Alex S Befeler, Lewis R Roberts, K Rajender Reddy, Denise Harnois, Josep M Llovet, Daniel Normolle, Jackie Dalhgren, David Chia, Anna S Lok, Paul D Wagner, Sudhir Srivastava, Myron Schwartz.   

Abstract

BACKGROUND & AIMS: Alpha-fetoprotein (AFP) is widely used as a surveillance test for hepatocellular carcinoma (HCC) among patients with cirrhosis. Des-gamma carboxy-prothrombin (DCP) and lectin-bound AFP (AFP-L3%) are potential surveillance tests for HCC. The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels.
METHODS: We conducted a large phase 2 biomarker case-control study in 7 academic medical centers in the United States. Controls were patients with compensated cirrhosis and cases were patients with HCC. AFP, DCP, and AFP-L3% levels were measured blinded to clinical data in a central reference laboratory.
RESULTS: A total of 836 patients were enrolled: 417 (50%) were cirrhosis controls and 419 (50%) were HCC cases, of which 208 (49.6%) had early stage HCC (n = 77 very early, n = 131 early). AFP had the best area under the receiver operating characteristic curve (0.80, 95% confidence interval [CI]: 0.77-0.84), followed by DCP (0.72, 95% CI: 0.68-0.77) and AFP-L3% (0.66, 95% CI: 0.62-0.70) for early stage HCC. The optimal AFP cutoff value was 10.9 ng/mL leading to a sensitivity of 66%. When only those with very early HCC were evaluated, the area under the receiver operating characteristic curve for AFP was 0.78 (95% CI: 0.72-0.85) leading to a sensitivity of 65% at the same cutoff.
CONCLUSIONS: AFP was more sensitive than DCP and AFP-L3% for the diagnosis of early and very early stage HCC at a new cutoff of 10.9 ng/mL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362088      PMCID: PMC2704256          DOI: 10.1053/j.gastro.2009.04.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

Authors:  Kelly A Gebo; Geetanjali Chander; Mollie W Jenckes; Khalil G Ghanem; H Franklin Herlong; Michael S Torbenson; Samer S El-Kamary; Eric B Bass
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis.

Authors:  M Ono; H Ohta; M Ohhira; C Sekiya; M Namiki
Journal:  Tumour Biol       Date:  1990

Review 4.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 5.  Hepatocellular carcinoma: recent trends in the United States.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.

Authors:  Jiro Ikoma; Masahiko Kaito; Tomoaki Ishihara; Naoki Nakagawa; Akira Kamei; Naoki Fujita; Motoh Iwasa; Shigenori Tamaki; Shozo Watanabe; Yukihiko Adachi
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

7.  Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.

Authors:  Jorge A Marrero; Grace L Su; Wei Wei; Dawn Emick; Hari S Conjeevaram; Robert J Fontana; Anna S Lok
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

8.  Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein.

Authors:  Y Sato; K Nakata; Y Kato; M Shima; N Ishii; T Koji; K Taketa; Y Endo; S Nagataki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

Review 9.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis.

Authors:  Samir Gupta; Stephen Bent; Jeffrey Kohlwes
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

10.  A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients.

Authors:  K Shiraki; K Takase; Y Tameda; M Hamada; Y Kosaka; T Nakano
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

View more
  218 in total

1.  Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.

Authors:  Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

3.  Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.

Authors:  Peter Richardson; Zhigang Duan; Jennifer Kramer; Jessica A Davila; Gia L Tyson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-07       Impact factor: 11.382

4.  The role of serum biomarkers in hepatocellular carcinoma surveillance.

Authors:  Jorge A Marrero; Keith S Henley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

5.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

6.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

7.  The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.

Authors:  Mengjun Wang; Karthik Devarajan; Amit G Singal; Jorge A Marrero; Jianliang Dai; Ziding Feng; Jo Ann S Rinaudo; Sudhir Srivastava; Alison Evans; Hie-Won Hann; Yinzhi Lai; Hushan Yang; Timothy M Block; Anand Mehta
Journal:  Cancer Prev Res (Phila)       Date:  2015-12-28

Review 8.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

9.  An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming.

Authors:  Li Zhang; Jiasheng Chen; Chunming Gao; Chuanmiao Liu; Kuihua Xu
Journal:  Med Biol Eng Comput       Date:  2018-03-16       Impact factor: 2.602

10.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.